Ground Swell Capital’s Sarepta Therapeutics SRPT Stock Holding History

Ground Swell Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,288	Closed	-$296K	–	106
2022 Q4	$296K	Buy	+2,288	New	+$265K	1.32%	21
2022 Q3	–	Sell	-3,444	Closed	-$258K	–	181
2022 Q2	$258K	Buy	+3,444	New	+$253K	0.47%	64
2014 Q3	$16K	Buy	763 +607	+389%	+$13.7K	0.03%	668
2014 Q2	$5K	Buy	+156	New	+$4.93K	0.01%	1103

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ground Swell Capital's SRPT Position: Q1 2023 in Review

Ground Swell Capital sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 2,288 shares — an estimated $296K sold.

Ground Swell Capital first reported a position in SRPT in Q2 2014 and held it in 4 quarters. The position peaked at $296K in Q4 2022. 425 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

Ground Swell Capital reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
Ground Swell Capital sold 2,288 Sarepta Therapeutics shares in Q1 2023, an estimated $296K.
Ground Swell Capital first reported a position in Sarepta Therapeutics in Q2 2014 and held it in 4 quarters.
Ground Swell Capital's Sarepta Therapeutics position peaked at $296K in Q4 2022.
425 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on Ground Swell Capital's 13F filing for Q1 2023, filed 8 May 2023.